Australia's TGA designates new orphan drug
This article was originally published in Scrip
Executive Summary
Australia's Therapeutics Goods Administration (TGA) has designated a new orphan drug: Novartis' Glivec (imatinib mesylate) in doses of 5mg and 100mg capsules and 100mg and 400mg tablets, for adjuvant therapy for gastrointestinal stromal tumour (GIST). It received designated status on October 1st.